AEMD יחס שווי שוק לנכסים נקיים aethlonmedical.com

Aethlon Medical (AEMD) risks are linked to a dependence on funding and FDA approvals, which triggers volatility. This chart of the market cap to book value ratio visualizes these fluctuations, where the metric level stands at 0.47. Stability is restored by the innovative Hemopurifier, which physically removes pathogens, as well as the steady growth in demand for unique filters in specialized clinics.

This indicator determines the ratio of a company's market value to its net assets, measuring the premium investors pay for the business's future potential. By analyzing the price-to-book value multiple, market participants assess the extent to which quotes are inflated relative to the actual balance sheet. An increasing ratio signals expectations of a breakthrough, while a decrease indicates fundamental weakening. For Aethlon Medical (AEMD), this metric reflects the speculative value of the Hemopurifier development. The current valuation relies exclusively on the FDA Breakthrough status and the success of oncology trials.